Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “sell” rating reissued by analysts at BMO Capital Markets in a report released on Monday.

Other analysts also recently issued reports about the company. Piper Jaffray Companies restated a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Jefferies Group restated a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target for the company in a research note on Wednesday, September 27th. Leerink Swann boosted their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $65.11.

Bristol-Myers Squibb (NYSE:BMY) traded up $1.00 on Monday, reaching $63.28. The company had a trading volume of 6,747,874 shares, compared to its average volume of 7,188,714. The company has a market cap of $103,570.00, a P/E ratio of 24.91, a PEG ratio of 2.16 and a beta of 1.18. Bristol-Myers Squibb has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.77 earnings per share. sell-side analysts predict that Bristol-Myers Squibb will post 2.99 EPS for the current year.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction dated Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Howard Capital Management raised its holdings in shares of Bristol-Myers Squibb by 0.5% during the 4th quarter. Howard Capital Management now owns 176,010 shares of the biopharmaceutical company’s stock worth $10,786,000 after buying an additional 804 shares in the last quarter. Cornerstone Financial Partners LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $260,000. Cornerstone Investment Partners LLC raised its holdings in shares of Bristol-Myers Squibb by 100.0% during the 4th quarter. Cornerstone Investment Partners LLC now owns 19,168 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 9,584 shares in the last quarter. Patten & Patten Inc. TN raised its holdings in shares of Bristol-Myers Squibb by 5.5% during the 4th quarter. Patten & Patten Inc. TN now owns 176,814 shares of the biopharmaceutical company’s stock worth $10,835,000 after buying an additional 9,251 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Bristol-Myers Squibb by 11.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 44,579 shares of the biopharmaceutical company’s stock worth $2,731,000 after buying an additional 4,569 shares in the last quarter. 69.75% of the stock is owned by institutional investors.

WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/22/bristol-myers-squibb-bmy-given-sell-rating-at-bmo-capital-markets.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.